Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Toward primary prevention of extra-medical OxyContin® use among young people.

Deandrea DC, Troost JP, Anthony JC.

Prev Med. 2013 Sep;57(3):244-6. doi: 10.1016/j.ypmed.2013.05.004. Epub 2013 May 20.

2.

Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.

Degenhardt L, Larance B, Bruno R, Lintzeris N, Ali R, Farrell M.

Addiction. 2015 Feb;110(2):226-37. doi: 10.1111/add.12746. Epub 2014 Oct 30.

PMID:
25358480
3.

Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.

Cicero TJ, Inciardi JA, Muñoz A.

J Pain. 2005 Oct;6(10):662-72.

PMID:
16202959
4.

Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.

Cicero TJ, Ellis MS.

JAMA Psychiatry. 2015 May;72(5):424-30. doi: 10.1001/jamapsychiatry.2014.3043.

PMID:
25760692
5.

Correlates of extramedical use of OxyContin versus other analgesic opioids among the US general population.

Martins SS, Storr CL, Zhu H, Chilcoat HD.

Drug Alcohol Depend. 2009 Jan 1;99(1-3):58-67. doi: 10.1016/j.drugalcdep.2008.06.013. Epub 2008 Aug 15.

6.

Non-medical use of OxyContin Tablets in the United States.

Sees KL, Di Marino ME, Ruediger NK, Sweeney CT, Shiffman S.

J Pain Palliat Care Pharmacother. 2005;19(2):13-23.

PMID:
16061457
7.

Impact of abuse-deterrent OxyContin on prescription opioid utilization.

Hwang CS, Chang HY, Alexander GC.

Pharmacoepidemiol Drug Saf. 2015 Feb;24(2):197-204. doi: 10.1002/pds.3723. Epub 2014 Nov 13.

PMID:
25393216
8.

The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.

Degenhardt L, Bruno R, Ali R, Lintzeris N, Farrell M, Larance B.

Drug Alcohol Depend. 2015 Jun 1;151:56-67. doi: 10.1016/j.drugalcdep.2015.02.038. Epub 2015 Mar 16.

PMID:
25910850
9.

Prescription OxyContin abuse among patients entering addiction treatment.

Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG.

Am J Psychiatry. 2007 Nov;164(11):1750-6.

10.

Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.

Gosai P, Ducharme MP, Godfrey AR, Freeman JC, Monif T, Kumar KS, Kumar S, Mudnaik R, Katikaneni P.

Int J Clin Pharmacol Ther. 2013 Nov;51(11):895-907. doi: 10.5414/CP201764.

PMID:
23673291
11.
13.

Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.

Gudin J, Levy-Cooperman N, Kopecky EA, Fleming AB.

Pain Med. 2015 Nov;16(11):2142-51. doi: 10.1111/pme.12834. Epub 2015 Jun 22.

PMID:
26108255
14.

A profile of OxyContin addiction.

Hays LR.

J Addict Dis. 2004;23(4):1-9.

PMID:
15339710
15.

Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.

McNaughton EC, Coplan PM, Black RA, Weber SE, Chilcoat HD, Butler SF.

J Med Internet Res. 2014 May 2;16(5):e119. doi: 10.2196/jmir.3397.

16.
17.

CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005-2013.

Johnson NB, Hayes LD, Brown K, Hoo EC, Ethier KA; Centers for Disease Control and Prevention (CDC).

MMWR Suppl. 2014 Oct 31;63(4):3-27.

PMID:
25356673
18.

Discrepancies in prevalence estimates in two national surveys for nonmedical use of a specific opioid product versus any prescription pain reliever.

Biondo G, Chilcoat HD.

Drug Alcohol Depend. 2014 Jan 1;134:396-400. doi: 10.1016/j.drugalcdep.2013.10.005. Epub 2013 Oct 24.

19.

Confidence interval estimation in R-DAS.

Vsevolozhskaya OA, Anthony JC.

Drug Alcohol Depend. 2014 Oct 1;143:95-104. doi: 10.1016/j.drugalcdep.2014.07.017. Epub 2014 Aug 17.

PMID:
25175545
20.

Companies to pay $39.5m in OxyContin and Risperdal cases.

McCarthy M.

BMJ. 2015 Dec 31;351:h7018. doi: 10.1136/bmj.h7018. No abstract available.

PMID:
26721284

Supplemental Content

Support Center